Influence of a Laser-Lok Surface on Immediate Functional Loading of Implants in Single-Tooth Replacement: Three-Year Results of a Prospective Randomized Clinical Study on Soft Tissue Response and Esthetics

2015 ◽  
Vol 35 (6) ◽  
pp. 865-875 ◽  
Author(s):  
Renzo Guarnieri ◽  
Maurizio Grande ◽  
Stefano Ippoliti ◽  
Vincenzo Iorio-Siciliano ◽  
Francesco Riccitiello ◽  
...  

2014 ◽  
Vol 34 (1) ◽  
pp. 79-89 ◽  
Author(s):  
Davide Farronato ◽  
Francesco Mangano ◽  
Francesco Briguglio ◽  
Vincenzo Iorio-Siciliano ◽  
Francesco Riccitiello ◽  
...  


2011 ◽  
Vol 38 (8) ◽  
pp. 746-753 ◽  
Author(s):  
Jan Cosyn ◽  
Aryan Eghbali ◽  
Hugo De Bruyn ◽  
Kristiaan Collys ◽  
Roberto Cleymaet ◽  
...  




Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 151-158
Author(s):  
Katherine Yuxi Tai ◽  
Jad M. El Abiad ◽  
Carol D. Morris ◽  
Mark Christopher Markowski ◽  
Adam S. Levin

BACKGROUND: Checkpoint inhibitors and receptor tyrosine kinase inhibitors (RTKIs) have changed the standard of care for metastatic renal cell carcinoma (mRCC). Anecdotal evidence suggests these therapies may be less effective for treating bone than soft-tissue metastases. PURPOSE: We performed a retrospective review evaluating the relative clinical responses in soft-tissue and bone metastases in patients undergoing therapy using RTKIs and anti-programmed death-1 (PD-1) agents for mRCC. METHODS: Of the 2,212 patients in our institutional cancer registry with renal cell carcinoma (1997–2017), 68 (82 disease courses) were identified with measurable bone and soft-tissue metastases treated with RTKIs and/or PD-1s. Extent of metastasis was quantified at the time of therapy initiation (baseline) and at 3 months, 6 months, and 1 year. Changes in disease status were categorized as complete response, partial response, stable, mixed, or progression of disease according to RECIST v1.1 and MD Anderson criteria. These categories were further organized into “response to treatment” or “evidence of progression” to generate a generalized linear effects model with soft-tissue response as the independent variable and bone response as the dependent variable. Alpha = 0.05. RESULTS: Soft-tissue response correlated with bone response at 3 months (76 disease courses, p = 0.005) and 6 months (48 disease courses, p = 0.017). Of the patients with controlled soft-tissue disease, only 14 (19%) and 15 (32%) had progression in bone at 3 and 6 months, respectively. CONCLUSION: Contrary to anecdotal reports, osseous metastases do not appear to respond worse than soft-tissue metastases to treatment with these agents.



2008 ◽  
Vol 19 (8) ◽  
pp. 740-748 ◽  
Author(s):  
Mauro Donati ◽  
Vincenzo La Scala ◽  
Mauro Billi ◽  
Biagio Di Dino ◽  
Paolo Torrisi ◽  
...  


2014 ◽  
Vol 25 (4) ◽  
pp. 1383-1388 ◽  
Author(s):  
Sameh Ahemd Seifeldin ◽  
Maha Shawky ◽  
Saleem M. Hicham Nouman








Sign in / Sign up

Export Citation Format

Share Document